v3.26.1
Business, Liquidity and Basis of Presentation (Narrative) (Details) - USD ($)
$ in Thousands
6 Months Ended
Jul. 13, 2026
Jan. 15, 2026
Jun. 30, 2026
Dec. 31, 2025
Jun. 30, 2025
Dec. 31, 2024
Product Information [Line Items]            
Twelve-month escrow held     $ 7,616 $ 0    
Cash and cash equivalents     18,738 2,998 $ 9,534 $ 40,437
Accumulated deficit     2,144,089 $ 2,182,765    
Securities Purchase Agreement | Subsequent Event [Member]            
Product Information [Line Items]            
Number of shares issue and sell in transaction 23,035,227          
Proceeds from sale of common stock $ 255,000          
Series A Warrants | Securities Purchase Agreement | Subsequent Event [Member]            
Product Information [Line Items]            
Warrants issued to purchase shars of common stock 21,144,277          
Series B Warrants | Securities Purchase Agreement | Subsequent Event [Member]            
Product Information [Line Items]            
Warrants issued to purchase shars of common stock 33,797,214          
Private Placement [Member] | Securities Purchase Agreement | Subsequent Event [Member]            
Product Information [Line Items]            
Proceeds from sale of common stock $ 85,000          
MiNK Therapeutics, Inc.            
Product Information [Line Items]            
Receipt of payment of related party note receivable     5,200      
Zydus Lifesciences Ltd | Zydus Agreements [Member]            
Product Information [Line Items]            
Cash consideration received   $ 91,000 91,000      
Transaction expenses   5,800 5,800      
Twelve-month escrow held   7,500        
Escrow deposits including accrued interest     7,600      
Accrued interest     $ 100      
Zydus Lifesciences Ltd | Securities Purchase Agreement            
Product Information [Line Items]            
Cash consideration received   $ 7,200